Grants Search Results

The most common childhood cancer, acute lymphoblastic leukemia is a cancer of the bone marrow. Exciting new research shows that healthy normal bone marrow cells can protect leukemia cells from cancer drugs. Dr. Mullen's research aims to find ways to prevent normal marrow cells from protecting leukemia cells and thus make cancer drugs more effective.

Based on progress to date, Dr. Parihar was awarded a new grant in 2016 to fund an additional year of this Fellow award. Some children with cancer have solid tumors, or collections of abnormally growing cells, within their organs. These collections are made up of mostly tumor cells, but also of other cells that help the tumor hide from the bodys immune system and grow. Dr. Parihar is working to creating a new method to destroy these other cells found within solid tumors so that they cant help the tumor grow. This research aims to train the immune system to specifically recognize and kill these other cells, with the ultimate goal of curing the child of cancer.

Children with a rare brain cancer called glioblastoma rarely survive. The treatment of this cancer has not advanced for years because of difficulty accessing and growing the tumor cells. Recently, the tumor cells were found to harbor changes in a gene that is strongly conserved through evolution. Dr. Partridge has modeled the same genetic mutations in simple yeast cells to ask how the mutations impact the growth of cells and to find ways to effectively kill cells bearing the mutations. This research will then ask if similar therapies can be used to treat children with glioblastoma.

This grant is made with generous support from the "Henry Cermak Fund for Pediatric Cancer Research" created in memory of Henry Cermak and dedicated to his wish that "no one gets left out".

AML is the most common type of blood cancer. Normal blood stem cells have the capacity to produce all types of blood cells. However, impaired blood stem cells, as a consequence of genetic changes, play a central role in the initiation and progression of AML. Dr. Qian is researching how an alteration of expression of a critical gene, which is required for normal function of blood stem cells, causes AML. This study also aims to identify new therapeutic approaches to cure childhood leukemia by targeting the impaired blood stem cells.

Although most kids with a brain tumor survive the tumor itself, many have trouble doing activities that require attention and memory, and they often have difficulty fitting in with peers. Both types of difficulty could be related to changes in their brain structure or function, but research on this hasn'’t been done yet. Dr. Hoskinson is looking at whether there's a connection between these changes in brain structure and function and how kids get along with their peers. If there is, this research aims to help predict which kids will have social problems after treatment and identify ways to help.

Langerhans cell histiocytosis (LCH) is a very rare type of neoplasm of the blood that has not been well investigated. It has been traditionally excluded from the major cooperative research groups, and thus considered an orphan disease. However, LCH affects many children. This consortium uses a uniform treatment while investigating the biology of the disease to seek for better therapeutic targets. Awarded at Dana-Farber Cancer Institute and transferred to St. Jude Children's Research Hospital. Funds administered by St. Jude Children's Research Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

Only 45% of children with high-risk neuroblastoma are cured. The New Approaches to Neuroblastoma Therapy consortium links laboratory and clinical investigators to develop therapies and test them at 14 neuroblastoma centers. This consortium aims to improve immunotherapy, improve treatment of tumors, define gene changes in tumors for new treatments, and improve prediction of outcome with a "biomarker" test for blood and bone marrow. Funds administered by Children's Hospital Los Angeles.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.